RadNet Inc
Change company Symbol lookup
Select an option...
RDNT RadNet Inc
PNM PNM Resources Inc
ALB Albemarle Corp
AMBC Ambac Financial Group Inc
ASUR Asure Software Inc
MRK Merck & Co Inc
AMR Alpha Metallurgical Resources Inc
AAL American Airlines Group Inc
ADMS Adamas Pharmaceuticals Inc
MVIS MicroVision Inc

Health Care : Health Care Providers & Services | Small Cap Blend
Company profile

RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. As of December 31, 2016, the Company had in operation 257 MRI systems, 157 CT systems, 47 PET or combination PET/CT systems, 48 nuclear medicine systems, 479 X-ray systems, 279 mammography systems, 551 ultrasound systems and 104 fluoroscopy systems.

Closing Price
Day's Change
-0.47 (-2.02%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Ocugen's stock is up after sharing preprint about COVID-19 vaccine effectiveness against lesser known Brazilian variant

10:51 am ET May 3, 2021 (MarketWatch)

Shares of Ocugen Inc. (OCGN) were up 20.2% in trading on Monday after the Pennslyvania company said a COVID-19 vaccine it is contracted to develop with Indian biotechnology firm Bharat Biotech International Ltd. is "potentially" effective against B., or P.2., a variant first identified in Brazil in April 2020. The variant has been designated a variant of interest in the U.S. but is not considered a more serious variant of concern like the B.1.1.7. out of the U.K. or the P.1, which was also first identified in Brazil, according to the Centers for Disease Control and Prevention (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Interest). The study (https://www.biorxiv.org/content/10.1101/2021.04.30.441559v1%7CNEW) cited by Ocugen is a preprint, which is preliminary medical research that has not been peer-reviewed, and it compared IgG antibody titers in people who had received the shots to those who have recovered from COVID-19. The study was conducted in a lab and included 61 sera samples, two of which had the B. variant. Ocugen has said it is developing Bharat's vaccine, which was approved in India in January, for the U.S. but has not yet initiated clinical trials for this market. Ocugen's stock has soared 729.8% since the start of the year, while the S&P 500 is up 11.3%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com


(END) Dow Jones Newswires

May 03, 2021 10:51 ET (14:51 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.